ArticleAmerican journal of translational research2015
The anti-apoptosis effect of MLAA-34 in leukemia and the β-catenin/T cell factor 4 protein pathway.
Article in American journal of translational research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
6 citing papers in PubMed, 8 citations in OpenAlex.
- MLAA-34 knockdown shows enhanced antitumor activity via JAK2/STAT3 signaling pathway in acute monocytic leukemia.Journal of Cancer · 2020Article
- Keratin 6A gene silencing suppresses cell invasion and metastasis of nasopharyngeal carcinoma via the β‑catenin cascade.Molecular medicine reports · 2019Article
- C59T mutation in exon 2 of monocytic leukemia-associated antigen-34 gene indicates a high risk of recurrence of acute myeloid leukemia.Oncology letters · 2017Article
- Prokaryotic expression of MLAA-34 and generation of a novel human ScFv against MLAA-34 by phage display technology.Oncotarget · 2017Article
- Bioinformatic prediction and functional characterization of human KIAA0100 gene.Journal of pharmaceutical analysis · 2017Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective This study aims to observe the effects of MLAA-34 gene in leukemia and explore its mechanism. Methods MLAA-34 RNAi vector was constructed. NOD/SCID mice and 293T cells, K562 cells, HL60 cells and U937 cells were used in this study. They were divided into MLAA-34-siRNA group and control group. The proliferation ability and apoptosis of cells were detected. The expression levels of β-Catenin and TCF 4 were determined using western blotting and immunohistochemical methods. Results There was significant correlation between MLAA-34 gene and U937 cell proliferation, the apoptosis rates of U937 cells with siRNA infection were higher than that of control group. There were significant differences in the expression levels of β-Catenin and TCF 4 between U937 cells and U937 with MLAA-34-siRNA cells group. Conclusions MLAA-34 gene had anti-apoptotic effect in leukemia, which maybe through the β-Catenin/TCF 4 pathway.
Indexed as
Identifiers
26807175PMC4697707W2400457897What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.